Drug intelligence / Profile preview

ceftriaxone + rifampin

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

A combination antibiotic therapy consisting of ceftriaxone, a third-generation cephalosporin, and rifampin, an antimicrobial agent. Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while rifampin inhibits bacterial RNA synthesis by binding to the beta-subunit of DNA-dependent RNA polymerase. This combination is primarily used for treating bacterial meningitis, particularly pneumococcal meningitis, where it has been shown to decrease lipoteichoic acid concentrations in cerebrospinal fluid and reduce neuronal damage.

Targets

RNAP (Bacterial dna-dependent RNA polymerase)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ceftriaxone + rifampin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftriaxone + rifampin.

Explore the full profile